Uncomplicated Urinary Tract Infection Market Size was USD 927 Million in 2021

 Breaking News
  • No posts were found

Uncomplicated Urinary Tract Infection Market Size was USD 927 Million in 2021

November 29
15:27 2022
Uncomplicated Urinary Tract Infection Market Size was USD 927 Million in 2021

The Uncomplicated Urinary Tract Infections Market report provides current treatment practices, emerging drugs, Uncomplicated Urinary Tract Infections market share of the individual therapies, current and forecasted Uncomplicated Urinary Tract Infections market Size from 2019 to 2032 segmented by seven major markets.

  

Key takeaways from the Uncomplicated Urinary Tract Infections Market Research Report

  • In 2021, the total market size of Uncomplicated Urinary Tract Infection was USD 927 million which is expected to rise during the study period (2019–2032).
  • In the year 2021, total Diagnosed Cases of Uncomplicated Urinary Tract Infection was 19,624 cases in the 7MM which are expected to grow during the study period, i.e., 2019–2032.
  • Uncomplicated Urinary Tract Infection Market Companies are working such as GlaxoSmithKline, Iterum Therapeutics, Inmunotek, Janssen Pharmaceuticals, Fimbrion Therapeutics, and others.
  • Uncomplicated Urinary Tract Infection Pipeline therapies such as Phenazopyridine Hydrochloride Tables, USP 200 mg, Sulopenem-Etzadroxil/Probenecid, Ciprofloxacin, PP4001, Gepotidacin, Nitrofurantoin, Ciprofloxacin, Omadacycline tablets, Nitrofurantoin capsules, Canephron® N, Fosfomycin trometamol, and others.

 

For further information on the Uncomplicated Urinary Tract Infection market impact by therapies, download the Uncomplicated Urinary Tract Infection sample @ Uncomplicated Urinary Tract Infection Market Size

 

Uncomplicated Urinary Tract Infection Overview

Urinary tract infection is the most common bacterial infection caused by a range of pathogens, but most commonly by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis, and Staphylococcus saprophyticus. A UTI can develop in any part of the urinary tract, including the urethra, bladder, ureters, or kidneys. They are classified as either complicated or uncomplicated. Uncomplicated UTI typically affect individuals who are otherwise healthy and have no structural or neurological urinary tract abnormalities. Complicated UTI is associated with factors that compromise the urinary tract or host defense. Infection in men, children, and pregnant women are considered complicated, as most of these cases involve some urologic abnormality. Other characteristics that denote a complicated infection include immunosuppressive conditions, diabetes, catheterization, renal transplantation, and neurogenic bladder. Consequently, uUTI occur in otherwise healthy, adult, non-pregnant females.

 

Uncomplicated Urinary Tract Infection Epidemiology Segmentation in the 7MM

  • Uncomplicated Urinary Tract Infection epidemiology [segmented as Total Occurrence-specific cases of Uncomplicated Urinary Tract Infection,
  • Total Diagnosed Cases of Uncomplicated Urinary Tract Infection,
  • Total Age-specific Cases of Uncomplicated Urinary Tract Infection,
  • Total Pathogen-specific Cases of Uncomplicated Urinary Tract Infection
  • Total Treated Cases (across lines) of Uncomplicated Urinary Tract Infection]

 

Keen to learn how Uncomplicated Urinary Tract Infection Epidemiological Trends are going to appear in 2032 for the 7 MM, Download @ Uncomplicated Urinary Tract Infection Epidemiological Insights

 

Uncomplicated Urinary Tract Infection Emerging Drugs

 GSK2140944/Gepotidacin (GlaxoSmithKline)

Gepotidacin (GSK2140944), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, is in development to treat uUTI. Gepotidacin is the first in a new class of antibiotics developed at GSK in 2007 with a novel “dual targeting” MOA and oral formulation.  

Sulopenem Etzadroxil – Probenecid (Iterum Therapeutics)

Iterum Therapeutics is developing its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against various gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics. Sulopenem is an orally bioavailable, broad-spectrum penem β-lactam antibiotic that is being developed to treat infections caused by multi-drug resistant bacteria. 

Uromune/MV140 (Inmunotek)

Uromune is a glycerinated suspension containing whole cell-inactivated bacteria for sublingual administration. It is administered by spraying over the sublingual area. Uromune is intended to be self-administered by the patient.

 

Uncomplicated Urinary Tract Infection Market Outlook

Urinary Tract Infection is an infection in any part of the urinary system, including kidneys, bladder, ureters, and urethra, has been categorized into uncomplicated and complicated UTI. Uncomplicated Urinary Tract Infection typically affects individuals who are otherwise healthy and have no structural or neurological urinary tract abnormalities. In contrast, complicated UTI are associated with factors that compromise the urinary tract or host defense, including urinary obstruction, immunosuppression, renal failure, renal transplantation, pregnancy, indwelling catheters or other drainage devices.

 

Uncomplicated Urinary Tract Infection Treatment Market

Antibiotics are still considered the gold standard of UTI treatments and are the first line of treatment for UTI. The antimicrobial agents most commonly used to treat uUTI include the combination drug trimethoprim and sulfamethoxazole (TMP-SMX), trimethoprim, β-lactams, fluoroquinolones, nitrofurantoin, and fosfomycin tromethamine. Oral treatment with fosfomycin trometamol and nitrofurantoin (e.g., nitrofurantoin monohydrate/macrocrystals) along with TMP-SMX are considered first-line treatment. In female patients with mild to moderate symptoms, symptomatic therapy (e.g. Ibuprofen) may be considered in consultation with individual patients as an alternative to antimicrobial treatment.

 

Discover more about therapy set to grab substantial Uncomplicated Urinary Tract Infection Market Insight Report @ Uncomplicated Urinary Tract Infection Market Landscape

 

Scope of the Uncomplicated Urinary Tract Infection Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Forecast Period- 2022-2032
  • Uncomplicated Urinary Tract Infection Market Companies are working such as GlaxoSmithKline, Iterum Therapeutics, Inmunotek, Janssen Pharmaceuticals, Fimbrion Therapeutics, and others.
  • Uncomplicated Urinary Tract Infection Pipeline therapies such as Phenazopyridine Hydrochloride Tables, USP 200 mg, Sulopenem-Etzadroxil/Probenecid, Ciprofloxacin, PP4001, Gepotidacin, Nitrofurantoin, Ciprofloxacin, Omadacycline tablets, Nitrofurantoin capsules, Canephron® N, Fosfomycin trometamol, and others.
  • Uncomplicated Urinary Tract Infection Market Drivers, Uncomplicated Urinary Tract Infection Market Barriers, Market Access, SWOT Analysis, Unmet Needs

 

Table of Content

1. Key Insights

2. Uncomplicated Urinary Tract Infection Report Introduction

3. Uncomplicated Urinary Tract Infection Market Overview at a Glance

4. Executive Summary of Uncomplicated Urinary Tract Infection

5. Uncomplicated Urinary Tract Infection Epidemiology and Market Methodology

6. Uncomplicated Urinary Tract Infection Disease Background and Overview

7. Uncomplicated Urinary Tract Infection Diagnosis

8. Prevention of UTI

9. Diagnostic Guidelines

10. Current Treatment Practices of Uncomplicated UTI

11. Uncomplicated Urinary Tract Infection Treatment Guidelines

12. Uncomplicated Urinary Tract Infection Epidemiology and Patient Population

13. Uncomplicated Urinary Tract Infection Patient Journey

14. Key Endpoints in Uncomplicated UTI Clinical Trials

15. Uncomplicated Urinary Tract Infection Emerging Therapies

16. Uncomplicated Urinary Tract Infection: 7 Major Market Analysis

17. Uncomplicated Urinary Tract Infection Market Access and Reimbursement

18. Uncomplicated Urinary Tract Infection Market Drivers

19. Uncomplicated Urinary Tract Infection Market Barriers

20. SWOT Analysis

21. Unmet Needs

22. Appendix

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

 

Know which therapy is expected to score the touchdown first @ Uncomplicated Urinary Tract Infection Market Drivers and Barriers

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

Related Articles

Categories